Open access
Open access
Powered by Google Translator Translator

Radiation Oncology

Review: Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer

30 Apr, 2021 | 08:31h | UTC

Evolution and Current Status of the Multidisciplinary Management of Locally Advanced Rectal Cancer – JCO Oncology Practice

 


M-A: Chemotherapy and radiotherapy in locally advanced head and neck cancer

15 Apr, 2021 | 06:29h | UTC

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis – The Lancet Oncology

 

Commentary on Twitter

 


RCT: No benefit from palliative radiotherapy after esophageal cancer stenting

18 Mar, 2021 | 08:52h | UTC

Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial – The Lancet Gastroenterology & Hepatology

 


Cohort study: Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer

14 Mar, 2021 | 20:09h | UTC

Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer

7 Mar, 2021 | 19:28h | UTC

News Release: New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer – World Health Organization

Technical Document: Technical specifications of radiotherapy equipment for cancer treatment

 

 


M-A: Local salvage therapies after radiotherapy for prostate cancer

3 Mar, 2021 | 08:06h | UTC

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) – European Urology (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


RCT: Endoscopic surgery improves survival compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma

28 Feb, 2021 | 20:45h | UTC

Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet Oncology

Commentary: Endoscopic Nasopharyngectomy vs IMRT for Previously Treated, Resectable, Locally Recurrent Nasopharyngeal Carcinoma – The ASCO Post

 


Guidelines in the management of CNS tumors

23 Feb, 2021 | 01:09h | UTC

Guidelines in the management of CNS tumors – Journal of Neuro-Oncology

 


Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update

21 Feb, 2021 | 21:47h | UTC

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 


RCT: Radiopharmaceutical therapy vs. cabazitaxel in patients with metastatic castration-resistant prostate cancer

15 Feb, 2021 | 00:29h | UTC

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Radionuclide Tx Wins in Third-Line Metastatic CRPC – MedPage Today

 


RCT: Total Body Irradiation vs. Chemotherapy Conditioning in Childhood ALL

9 Feb, 2021 | 00:39h | UTC

Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study – Journal of Clinical Oncology

Commentary: TBI Beats Chemoconditioning for ALL Transplants in Children – Medscape (free registration required)

 

Commentary on Twitter

 


Radiation therapy for small-cell lung cancer: ASCO Guideline endorsement of an ASTRO Guideline

29 Jan, 2021 | 01:27h | UTC

Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline – Journal of Clinical Oncology

 


ASCO Guideline Update: Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer

28 Jan, 2021 | 01:17h | UTC

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 


Randomized trial: Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer

28 Jan, 2021 | 01:09h | UTC

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial – Journal of Clinical Oncology

 

Commentary on Twitter

 


Randomized trial: Ultra-hypofractionated vs. conventionally fractionated radiotherapy for prostate cancer

19 Jan, 2021 | 01:14h | UTC

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 


CSCO and ASCO Guideline: Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma

15 Jan, 2021 | 08:14h | UTC

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline – Journal of Clinical Oncology

 


Randomized trial: Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) improve outcomes vs. traditional approach in locally advanced rectal cancer

12 Jan, 2021 | 01:12h | UTC

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Meta-analysis: Total neoadjuvant therapy vs. standard therapy in locally advanced rectal cancer

12 Jan, 2021 | 01:10h | UTC

Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis – JAMA Network Open

Commentaries: Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the Way AND Total Neoadjuvant Therapy Improves Rectal Cancer Pathologic Response – Physician’s Weekly

Related meta-analysis (just published): Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials – Cancers

 

Commentary on Twitter

 


Randomized trial: Among patients with advanced rectal cancer, short-course radiotherapy followed by chemotherapy before total mesorectal excision reduces disease-related treatment failure compared to standard treatment

15 Dec, 2020 | 01:29h | UTC

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial – The Lancet Oncology

 

Commentary on Twitter

 


Short review: How to diagnose and manage radiation therapy cardiotoxicity

6 Dec, 2020 | 23:27h | UTC

How to Diagnose and Manage Radiation Cardiotoxicity – JACC: CardioOncology

 


Radiation therapy for rectal cancer: Executive summary of an ASTRO clinical practice guideline

28 Oct, 2020 | 08:45h | UTC

Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline – Practical Radiation Oncology

Commentaries: ASTRO issues clinical guideline on radiation therapy for rectal cancer AND ASTRO Issues Guideline on Radiation Therapy for Rectal Cancer – Physician’s Weekly

 

Commentary on Twitter

 


[Abstract Only] Meta-analysis: Adjuvant vs. early salvage radiotherapy for the treatment of localized and locally advanced prostate cancer

29 Sep, 2020 | 10:04h | UTC

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data – The Lancet

Commentaries: For Radiotherapy After Radical Prostatectomy, Salvage Therapy Should Be “Standard of Care” – NEJM Journal Watch AND Prostate cancer patients could be spared radiotherapy after surgery as new research suggests there is no benefit and it could be carried out later if the disease comes back – The Daily Mail

 


Randomized trials: Salvage radiotherapy vs. adjuvant radiotherapy after radical prostatectomy

29 Sep, 2020 | 10:03h | UTC

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial – The Lancet

Related articles: Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial – The Lancet Oncology (free registration required) AND Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial – The Lancet Oncology (free registration required)

Commentaries: For Radiotherapy After Radical Prostatectomy, Salvage Therapy Should Be “Standard of Care” – NEJM Journal Watch AND Prostate cancer patients could be spared radiotherapy after surgery as new research suggests there is no benefit and it could be carried out later if the disease comes back – The Daily Mail

 


Advanced Prostate Cancer: AUA/ASTRO/SUO Guidelines

24 Sep, 2020 | 09:15h | UTC

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I – The Journal of Urology

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II – The Journal of Urology

 


[ESMO2020 press release – Not published yet] Randomized trial: No benefit for post-operative radiotherapy in non-small-cell lung cancer

22 Sep, 2020 | 09:23h | UTC

No benefit for post-operative radiotherapy in non-small-cell lung cancer – European Society of Medical Oncology

Commentary: Phase 3 Trial Results Do Not Support PORT in Resected Stage IIIAN2 NSCLC – Targeted Oncology

 


Stay Updated in Your Specialty

No spam, just news.